TapewireFind a company

person · Reporting owner

NOUGUES MAXIMO F

Disclosed activity across 1 company

Tapewire entity
31418
SEC CIK
0001758507

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
PUMA BIOTECHNOLOGY, INC.PBYI · Entity 5478Chief Financial OfficerJuly 06, 2026July 09, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

PUMA BIOTECHNOLOGY, INC.

Report date July 06, 2026 · Filed July 09, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect230,637 Reported balance After 2026-07-06 transaction · row 1
1 source row

Row 1 · 2026-07-06 · Sale · Disposed 9,386 · Balance 230,637

F1: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020.

Filing footnotes · ownership attribution and instrument terms

F1: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 06, 2026 Filed Jul 9, 2026 00:18 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCommon Stock 9,386 $8.26 $77,556.52
Disclosure

SEC source: 0001437749-26-023077 · rdgdoc.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 230,637

F1 · kind: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020.

Read SEC document
February 18, 2026 Filed Feb 21, 2026 01:28 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 GrantStock Option (Right to Buy) · Derivative 66,541 $0.00 Strike: $6.68 $0.00
Disclosure

SEC source: 0001437749-26-004946 · rdgdoc.xml · derivative · entry 2

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,541

Underlying: Common Stock · 66,541 shares

Expires 2036-02-17

F2 · derivative.exercise_date: Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares subject thereto on each of July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to the Reporting Person's continued service with the Company through the applicable vesting date.

Read SEC document
February 18, 2026 Filed Feb 21, 2026 01:28 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 GrantCommon Stock 46,739 $0.00 $0.00
Disclosure

SEC source: 0001437749-26-004946 · rdgdoc.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 240,023

F1 · shares: Represents Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to the Reporting Person's continued service with the Company through the applicable vesting date.

F1 · price: Represents Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to the Reporting Person's continued service with the Company through the applicable vesting date.

Read SEC document
January 07, 2026 Filed Jan 9, 2026 01:14 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCommon Stock 6,405 $5.88 $37,655.00
Disclosure

SEC source: 0001437749-26-000921 · rdgdoc.xml · nonDerivative · entry 2

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 193,284

F1 · kind: Adoption date of referenced 10b5-1(c) plan is: 12-14-2020

Read SEC document
January 06, 2026 Filed Jan 9, 2026 01:14 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCommon Stock 4,540 $5.84 $26,531.76
Disclosure

SEC source: 0001437749-26-000921 · rdgdoc.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 199,689

F1 · kind: Adoption date of referenced 10b5-1(c) plan is: 12-14-2020

Read SEC document
July 09, 2025 Filed Jul 11, 2025 00:56 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCommon Stock 3,935 $3.54 $13,910.23
Disclosure

SEC source: 0001437749-25-022551 · rdgdoc.xml · nonDerivative · entry 2

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 204,229

F1 · kind: Adoption date of referenced 10b5-1(c) plan is: 12-14-2020

Read SEC document
July 08, 2025 Filed Jul 11, 2025 00:56 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCommon Stock 5,587 $3.53 $19,738.87
Disclosure

SEC source: 0001437749-25-022551 · rdgdoc.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 208,164

F1 · kind: Adoption date of referenced 10b5-1(c) plan is: 12-14-2020

Read SEC document
February 07, 2025 Filed Feb 11, 2025 23:58 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 GrantStock Option (Right to Buy) · Derivative 85,067 $0.00 Strike: $2.78 $0.00
Disclosure

SEC source: 0001437749-25-003461 · rdgdoc.xml · derivative · entry 2

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,067

Underlying: Common Stock · 85,067 shares

Expires 2035-02-06

F2 · derivative.exercise_date: Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares subject thereto on each of July 1, 2025, January 1, 2026, July 1, 2026 and January 1, 2027, subject to the Optionee's continued service with the Company through the applicable vesting date.

Read SEC document
February 07, 2025 Filed Feb 11, 2025 23:58 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 GrantCommon Stock 61,456 $0.00 $0.00
Disclosure

SEC source: 0001437749-25-003461 · rdgdoc.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 213,751

F1 · shares: Represents Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2025, January 1, 2026, July 1, 2026 and January 1, 2027, subject to the Grantee's continued service with the Company through the applicable vesting date.

Read SEC document
January 02, 2025 Filed Jan 4, 2025 00:33 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCommon Stock 10,227 $3.15 $32,232.44
Disclosure

SEC source: 0001437749-25-000365 · rdgdoc.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 152,295

F1 · kind: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.11 to $3.2101, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
July 17, 2024 Filed Jul 18, 2024 23:11 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCommon Stock 4,156 $3.70 $15,381.77
Disclosure

SEC source: 0001437749-24-023022 · rdgdoc.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 162,522

F1 · kind: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.6001 to $3.8901, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
July 02, 2024 Filed Jul 3, 2024 01:22 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCommon Stock 5,295 $3.27 $17,306.71
Disclosure

SEC source: 0001437749-24-022067 · rdgdoc.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 166,678

F1 · kind: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.2601 to $3.3101, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
February 12, 2024 Filed Feb 14, 2024 23:01 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 GrantStock Option (Right to Buy) · Derivative 59,946 $0.00 Strike: $6.36 $0.00
Disclosure

SEC source: 0001437749-24-004216 · rdgdoc.xml · derivative · entry 2

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,946

Underlying: Common Stock · 59,946 shares

Expires 2034-02-11

F2 · derivative.exercise_date: Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares subject thereto on each of July 1, 2024, January 1, 2025, July 1, 2025 and January 1, 2026, subject to the Optionee's continued service with the Company through the applicable vesting date.

Read SEC document
February 12, 2024 Filed Feb 14, 2024 23:01 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 GrantCommon Stock 43,307 $0.00 $0.00
Disclosure

SEC source: 0001437749-24-004216 · rdgdoc.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 171,973

F1 · shares: Represents Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2024, January 1, 2025, July 1, 2025 and January 1, 2026, subject to the Grantee's continued service with the Company through the applicable vesting date.

Read SEC document
January 03, 2024 Filed Jan 5, 2024 23:49 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCommon Stock 15,682 $4.49 $70,347.88
Disclosure

SEC source: 0001437749-24-000768 · rdgdoc.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 128,666

F1 · kind: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.3601 to $4.7101, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
July 03, 2023 Filed Jul 6, 2023 23:12 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCommon Stock 14,680 $3.31 $48,608.42
Disclosure

SEC source: 0001437749-23-019525 · rdgdoc.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 144,348

F1 · kind: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.24 to $3.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
February 10, 2023 Filed Feb 14, 2023 21:53 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 GrantStock Option (Right to Buy) · Derivative 81,399 $0.00 Strike: $4.39 $0.00
Disclosure

SEC source: 0001437749-23-003382 · rdgdoc.xml · derivative · entry 2

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,399

Underlying: Common Stock · 81,399 shares

Expires 2033-02-09

F2 · derivative.exercise_date: Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares subject thereto on each of July 1, 2023, January 1, 2024, July 1, 2024 and January 1, 2025, subject to the Optionee's continued service with the Company through the applicable vesting date.

Read SEC document
February 10, 2023 Filed Feb 14, 2023 21:53 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 GrantCommon Stock 58,601 $0.00 $0.00
Disclosure

SEC source: 0001437749-23-003382 · rdgdoc.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 159,028

F1 · shares: Represents Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2023, January 1, 2024, July 1, 2024 and January 1, 2025, subject to the Grantee's continued service with the Company through the applicable vesting date.

Read SEC document
January 03, 2023 Filed Jan 5, 2023 22:40 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCommon Stock 10,499 $4.18 $43,863.77
Disclosure

SEC source: 0001437749-23-000547 · rdgdoc.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,427

F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.13 to $4.1922, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
December 02, 2022 Filed Dec 6, 2022 21:30 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCommon Stock 159 $4.50 $715.15
Disclosure

SEC source: 0001437749-22-028558 · rdgdoc.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,926

F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.4601 to $4.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
November 02, 2022 Filed Nov 4, 2022 20:13 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCommon Stock 163 $2.25 $366.75
Disclosure

SEC source: 0001437749-22-026032 · rdgdoc.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,085

F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 20:40 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCommon Stock 165 $2.34 $385.34
Disclosure

SEC source: 0001437749-22-023679 · rdgdoc.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,248

F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.33 to $2.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
September 02, 2022 Filed Sep 7, 2022 20:44 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCommon Stock 164 $2.59 $424.69
Disclosure

SEC source: 0001437749-22-021986 · rdgdoc.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,413

F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.565 to $2.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
August 02, 2022 Filed Aug 5, 2022 01:34 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCommon Stock 161 $2.89 $465.29
Disclosure

SEC source: 0001437749-22-018993 · rdgdoc.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,577

F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program.

Read SEC document
July 05, 2022 Filed Jul 8, 2022 00:19 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCommon Stock 5,835 $2.63 $15,354.80
Disclosure

SEC source: 0001437749-22-016850 · rdgdoc.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,625

F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.60 to $2.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
July 05, 2022 Filed Aug 5, 2022 01:30 UTC Amendment PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCommon Stock 9,328 $2.63 $24,546.63
Disclosure

SEC source: 0001437749-22-018991 · rdgdoc.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,738

F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.60 to $2.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
June 02, 2022 Filed Jun 6, 2022 21:05 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCommon Stock 162 $1.92 $311.33
Disclosure

SEC source: 0001437749-22-014434 · rdgdoc.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,066

F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program.

Read SEC document
May 03, 2022 Filed May 4, 2022 22:43 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCommon Stock 165 $2.34 $386.12
Disclosure

SEC source: 0001437749-22-010926 · rdgdoc.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,228

F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program.

Read SEC document
April 04, 2022 Filed Apr 5, 2022 20:52 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCommon Stock 206 $3.08 $634.07
Disclosure

SEC source: 0001437749-22-008328 · rdgdoc.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,393

F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units

Read SEC document
March 03, 2022 Filed Mar 14, 2022 23:31 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 GrantStock Option (Right to Buy) · Derivative 88,824 $0.00 Strike: $2.33 $0.00
Disclosure

SEC source: 0001437749-22-006188 · rdgdoc.xml · derivative · entry 2

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,824

Underlying: Common Stock · 88,824 shares

Expires 2032-03-02

F2 · derivative.exercise_date: Subject to the Optionee's continued service with the Company through the applicable vesting date, the Option shall vest and become exercisable with respect to one-fourth (1/4th) of the Shares subject thereto on each of July 1, 2022, January 1, 2023, July 1, 2023 and January 1, 2024.

Read SEC document
March 03, 2022 Filed Mar 14, 2022 23:31 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 GrantCommon Stock 62,176 $0.00 $0.00
Disclosure

SEC source: 0001437749-22-006188 · rdgdoc.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,599

F1 · shares: Subject to the Grantee's continued service with the Company through the applicable vesting date, the Restricted Stock Units shall vest with respect to one-fourth (1/4th) of the Restricted Stock Units on each of July 1, 2022, January 1, 2023, July 1, 2023 and January 1, 2024.

Read SEC document
March 02, 2022 Filed Mar 4, 2022 22:14 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCommon Stock 169 $2.26 $382.28
Disclosure

SEC source: 0001437749-22-005306 · rdgdoc.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,423

F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units.

Read SEC document
February 02, 2022 Filed Feb 3, 2022 22:34 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCommon Stock 199 $2.48 $493.96
Disclosure

SEC source: 0001437749-22-002412 · rdgdoc.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,592

F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units.

Read SEC document
January 03, 2022 Filed Jan 5, 2022 22:04 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCommon Stock 7,484 $3.19 $23,870.97
Disclosure

SEC source: 0001437749-22-000444 · rdgdoc.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,791

F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.17 to $3.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
December 02, 2021 Filed Dec 6, 2021 23:37 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCommon Stock 162 $2.95 $477.90
Disclosure

SEC source: 0001437749-21-027954 · rdgdoc.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,275

F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units.

Read SEC document
November 02, 2021 Filed Nov 3, 2021 22:22 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCommon Stock 156 $5.67 $884.68
Disclosure

SEC source: 0001209191-21-062788 · doc4.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,437

F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units.

Read SEC document
October 04, 2021 Filed Oct 6, 2021 21:20 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCommon Stock 161 $6.20 $998.22
Disclosure

SEC source: 0001437749-21-023380 · rdgdoc.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,593

F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units.

Read SEC document
September 02, 2021 Filed Sep 3, 2021 23:40 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCOMMON STOCK 155 $7.51 $1,164.21
Disclosure

SEC source: 0001209191-21-054896 · doc4.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,754

F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units.

Read SEC document
August 02, 2021 Filed Aug 3, 2021 21:52 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCOMMON STOCK 154 $7.54 $1,161.48
Disclosure

SEC source: 0001209191-21-049435 · doc4.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,909

F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units.

Read SEC document
July 02, 2021 Filed Jul 6, 2021 21:43 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCOMMON STOCK 155 $9.26 $1,435.11
Disclosure

SEC source: 0001209191-21-045599 · doc4.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,063

F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units,

Read SEC document
June 02, 2021 Filed Jun 4, 2021 20:56 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCOMMON STOCK 152 $10.74 $1,632.63
Disclosure

SEC source: 0001209191-21-038294 · doc4.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,218

F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units.

Read SEC document
May 03, 2021 Filed May 5, 2021 20:44 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCOMMON STOCK 152 $9.91 $1,506.38
Disclosure

SEC source: 0001209191-21-030355 · doc4.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,370

F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units.

Read SEC document
April 05, 2021 Filed Apr 6, 2021 22:02 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCOMMON STOCK 155 $9.80 $1,519.45
Disclosure

SEC source: 0001209191-21-025730 · doc4.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,522

F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units.

Read SEC document
March 02, 2021 Filed Mar 4, 2021 21:48 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCOMMON STOCK 154 $10.14 $1,560.88
Disclosure

SEC source: 0001209191-21-017852 · doc4.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,677

F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units.

Read SEC document
February 17, 2021 Filed Feb 19, 2021 23:49 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 GrantStock Option (Right to Buy) · Derivative 78,209 $0.00 Strike: $12.02 $0.00
Disclosure

SEC source: 0001209191-21-012533 · doc4.xml · derivative · entry 2

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,209

Underlying: COMMON STOCK · 78,209 shares

Expires 2031-02-16

F2 · derivative.exercise_date: Subject to the Optionee's continued service with the Company through the applicable vesting date, the Option shall vest and become exercisable with respect to (i) one-third (1/3) of the Shares (as defined in the Plan) underlying the Option on the first anniversary of the vesting commencement date of January 1, 2021 (the "Vesting Commencement Date") and (ii) one-sixth (1/6th) of the Shares subject thereto on each of July 1, 2022, January 1, 2023, July 1, 2023, and January 1, 2024.

Read SEC document
February 17, 2021 Filed Feb 19, 2021 23:49 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 GrantCOMMON STOCK 55,595 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-012533 · doc4.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,831

F1 · shares: Subject to the Grantee's continued service with the Company through the applicable vesting date, the Restricted Stock Units shall vest with respect to (i) one-third (1/3) of the Restricted Stock Units on the first anniversary of the vesting commencement date of January 1, 2021 (the "Vesting Commencement Date") and (ii) one-sixth (1/6th) of the Restricted Stock Units on each of July 1, 2022, January 1, 2023, July 1, 2023 and January 1, 2024.

Read SEC document
February 02, 2021 Filed Feb 4, 2021 22:13 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCOMMON STOCK 179 $12.26 $2,194.67
Disclosure

SEC source: 0001209191-21-007808 · doc4.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,236

F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units.

Read SEC document
January 04, 2021 Filed Jan 6, 2021 23:48 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 SaleCOMMON STOCK 2,145 $10.22 $21,930.27
Disclosure

SEC source: 0001209191-21-002341 · doc4.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,415

F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.17 to $10.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
February 11, 2020 Filed Feb 14, 2020 02:34 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 GrantStock Option (Right to Buy) · Derivative 15,567 $0.00 Strike: $12.34 $0.00
Disclosure

SEC source: 0001209191-20-009464 · doc4.xml · derivative · entry 2

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,567

Underlying: COMMON STOCK · 15,567 shares

Expires 2030-02-10

F2 · derivative.exercise_date: The vesting commencement date of the option is January 1, 2020 ("Option Vesting Commencement Date"). The option vests (i) with respect to one-third (1/3rd) of the shares subject thereto on the first anniversary of the Option Vesting Commencement Date and (ii) with respect to 1/36th of the shares subject thereto on each monthly anniversary of the Option Vesting Commencement Date thereafter, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.

Read SEC document
February 11, 2020 Filed Feb 14, 2020 02:34 UTC PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 GrantCOMMON STOCK 15,560 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-009464 · doc4.xml · nonDerivative · entry 1

NOUGUES MAXIMO F · CIK 0001758507 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,560

F1 · shares: Represents Restricted Stock Units which vest (i) with respect to one-third (1/3rd) of the shares subject thereto on the first anniversary of the vesting commencement date of January 1, 2020 ("Vesting Commencement Date") and (ii) with respect to 1/36th of the shares subject thereto on each monthly anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.